The Lazarus Laboratory

Toronto, Ontario, Canada

Platelet.ca & Mytherapeutics.com

Link to our Publications:


PubMed


Google Scholar


Intravenous immunoglobulin (IVIg)


IVIg is a therapeutic preparation of antibodies derived from the plasma of healthy blood donors and is used to treat a number of different autoimmune diseases successfully. Our laboratory performs research attempting to understand how IVIg works and we are actively working on IVIg substitutes (e.g., antibodies to CD44 can mimic IVIg in ITP and arthitis). Opportunities for graduate students or postdoctoral fellows to work on mechanisms of action of IVIg or anti-CD44 are always available. Please contact Dr. Lazarus to discuss a project that might best suit you.

                          


Our laboratory is located in the heart of downtown Toronto within the Li Ka Shing knowledge Institute of St. Michael’s hospital. The Institute was built in 2011 and is dedicated to medical research. The research in our laboratory is focused on understanding mechanisms of action of antibody-based therapeutics to treat diseases of the immune system. We are also interested in the mechanism of action of how anti-D can prevent hemolytic disease of the fetus and newborn.

 

Why not consider applying to our lab!

 

Dr. Alan H. Lazarus, Ph.D.

Professor, University of Toronto

A great city to live and work in  

Autoimmune diseases like ITP

 

Immune thrombocytopenia (ITP) is an autoimmune disease where our immune system destroys our own platelets. As platelets are a key element helping to control blood loss (hemostasis), patients with ITP can have severe bleeding. One plasma-derived antibody therapeutic which can treat this disease is a product called anti-D and we study how anti-D may work in ITP. We are also interested in understanding the pathophysiology of this disease. Potential students or postdoctoral fellows are invited to contact Dr. Lazarus to talk about opportunities related to understanding and treating ITP or other autoimmune diseases.

Hemolytic disease of the fetus and newborn (HDFN)

 

HDFN occurs when a mother who does not express the RhD antigen on her red cells (RhD negative) gives rise to a child who expresses this antigen. HDFN can be successfully prevented by administering anti-D to the mother during and after pregnancy. In fact, this use of anti-D is one of the most successful therapeutic interventions we have in our immunology toolkit. Despite this, we have a very poor understanding of how anti-D actually works. Opportunities are available to work on a murine model. Contact Dr. Lazarus to discuss what opportunities could be available for you.

I'm a potential graduate student or I've recently graduated with my PhD, now what...

Intravenous immunoglobulin (IVIg)



                          


Immunology

Immune thrombocytopenia (ITP)

Antibody research

Hematology